Table 2.
Meconium antiretroviral (ARV) detection frequency among 107 infants and proportion of missed detection of 3rd trimester prescribed ARVs
| Meconium ARVa |
Number of infants with 3rd trimester exposure |
Missed ARV meconium detection (n, %) |
|---|---|---|
| SQV | 4 | 1 (25.0) |
| TFV | 67 | 18 (26.9) |
| LPV | 37 | 11 (29.7) |
| ATV | 47 | 14 (29.8) |
| EFV | 3 | 1 (33.3) |
| RAL | 9 | 3 (33.3) |
| DRV | 14 | 5 (35.7) |
| NFV | 10 | 4 (40.0) |
| ABC | 18 | 8 (44.4) |
| FTC | 60 | 27 (45.0) |
| 3TC | 63 | 38 (60.3) |
| NVP | 3 | 2 (66.7) |
| RTV | 88 | 63 (71.6) |
| d4T | 2 | 0 (100) |
a
SQV, saquinavir; TFV, tenofovir; LPV, lopinavir; ATV, atazanavir; EFV, efavirenz; RAL, raltegravir; DRV, darunavir; NFV, nelfinavir; ABC, abacavir; FTC, emtricitabine; 3TC, lamivudine; NVP, nevirapine; RTV, ritonavir; d4T, stavudine. Zidovudine (AZT) meconium drug detection shown separately due to other common exposure routes, including labor and delivery (L&D) and neonatal administration. No amprenavir exposure examples examined in this sample population.